[Clinical studies of SM-4300 in combination with antibiotics against severe bacterial infections].
SM-4300, a newly developed human immunoglobulin preparation was evaluated in 24 patients with severe bacterial infections and the following results were obtained. The clinical efficacy was excellent in 4 cases, good in 7, fair in 5, poor in 3 and unknown in 5 with the effective rate of 57.9%. No serious side effect nor abnormalities in laboratory findings due to administration of SM-4300 were observed except 1 case with slight elevation of GOT and GPT.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001419:Bacteria / Q000276:immunology; D001424:Bacterial Infections / Q000628:therapy*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy*; D013530:Surgical Wound Infection / Q000628:therapy
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300